Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
More encouraging news from MGC regarding the successful completion of its CimetrA™ pre-clinical trial. This is yet another big step forward for the company. Big pharma won't want to miss out on this soon. See results below. We operate in a highly acquisitive multi billion sector. Watch this space for licencing or a takeover of MGC in due course.
* "important milestone moment for the Company", as it continues to progress CimetrATM along the mandated clinical pathway.
* "In pre-clinical and clinical trials CimetrATM has demonstrated anti-inflammatory and immunomodulating effects, and can be designed for multiple therapeutic applications" .
.
* "Preclinical and clinical results to date have demonstrated CimetrATM's mechanism of action as an anti-inflammatory and immunomodulatory agent which is effective in the prevention of severe inflammation by its control of increased Cytokine production resulting from an infection of the different variants of SARS-CoV-2 (the virus responsible for COVID-19); and which is the forerunner of a Cytokine Storm, which is believed to be the main reason for mortality in severe COVID-19 patients".
* The results of this study are a critical step in advancing MGC's submission to the FDA, and for the final approval of CimetrATM as an Investigational New Drug in the US."
Good luck, Brighty
MGC keeps driving forward with regular news. Wont be long before the analysts prediction of 7.2p in 2022 translates into reality for 2023,their opinion hasnt changed !
Lol 7.2p I might break even, I think your alarm is going off
great update..hopefully we get the fda approval... directors reducing their salary also gives me confidence that they believe in their product
Great news today, strong recoveryy ahead this will be a hot sector this year and very vunerable to takover at current tiny mkt cap
Another box ticked on the list, long way to go. Still bottomed draw. Nice to see nod to the originality of the compound with the name drop of covid, shame they missed that boat.... and many others. Onwards and holding.